BioSpace News Archive

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced its completion of the 75,000 th whole human genome sequenced under its contract with the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). All genomes were sequenced in the company’s laboratory in Menlo Park, Ca

Alteogen Inc. (KOSDAQ:196170) announced today that it has entered into a non-exclusive, global license agreement with a Top Ten Pharmaceutical Company (TTPC), to use ALT-B4, Alteogen’s novel hyaluronidase- derived utilizing the Hybrozyme™ technology. ALT-B4 is a proprietary recombinant human hyaluronidase enzyme that enables large-volume su

Mayne Pharma Group Limited is pleased to announce the New Drug Application for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration.

Innovation in products spells competition in the global veterinary antiseptics market, says a recent report published by Transparency Market Research.

The global glioblastoma multiforme treatment market is anticipated to rise significantly owing to key players adopting competitive strategies such as merger and acquisitions for marketing.

The global clostridium vaccines market features a consolidated vendor landscape with a small number of players accounting for a major share in the market, notes Transparency Market Research.

Health care-acquired infections and associated outbreaks have risen in hospital settings, and have raised substantial concerns related to patients’ safety.

Skanska has signed a contract with the New York City Health and Hospital Corporation to renovate the North Central Bronx Hospital in Bronx, New York, USA.

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis, announced positive results from a PXL770 four-week placebo-controlled PK/PD study in 16 likely-NASH patients with insulin resistance.

To develop its registration trial of AK104 (Bi-specific Anti-PD1/CTLA-4 Antibody) in Cervical Cancer